Stokes Family Office LLC Sells 1,391 Shares of Bristol-Myers Squibb (NYSE:BMY)

Stokes Family Office LLC lowered its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 3.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 40,444 shares of the biopharmaceutical company’s stock after selling 1,391 shares during the quarter. Stokes Family Office LLC’s holdings in Bristol-Myers Squibb were worth $2,075,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Los Angeles Capital Management LLC increased its position in shares of Bristol-Myers Squibb by 24.5% during the 4th quarter. Los Angeles Capital Management LLC now owns 1,913,249 shares of the biopharmaceutical company’s stock valued at $98,169,000 after purchasing an additional 376,367 shares during the last quarter. First Horizon Advisors Inc. grew its position in Bristol-Myers Squibb by 2.3% in the 4th quarter. First Horizon Advisors Inc. now owns 93,408 shares of the biopharmaceutical company’s stock valued at $4,793,000 after acquiring an additional 2,075 shares during the last quarter. Summit Asset Management LLC grew its position in Bristol-Myers Squibb by 7.6% in the 4th quarter. Summit Asset Management LLC now owns 8,498 shares of the biopharmaceutical company’s stock valued at $436,000 after acquiring an additional 600 shares during the last quarter. West Family Investments Inc. grew its position in Bristol-Myers Squibb by 64.1% in the 4th quarter. West Family Investments Inc. now owns 6,096 shares of the biopharmaceutical company’s stock valued at $313,000 after acquiring an additional 2,381 shares during the last quarter. Finally, Fisher Asset Management LLC grew its position in Bristol-Myers Squibb by 130.7% in the 4th quarter. Fisher Asset Management LLC now owns 224,537 shares of the biopharmaceutical company’s stock valued at $11,521,000 after acquiring an additional 127,228 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Up 0.7 %

Shares of NYSE BMY traded up $0.29 during mid-day trading on Friday, reaching $43.99. 11,979,505 shares of the company were exchanged, compared to its average volume of 15,917,313. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The stock has a market cap of $89.17 billion, a price-to-earnings ratio of -14.19, a P/E/G ratio of 14.90 and a beta of 0.45. Bristol-Myers Squibb has a 1 year low of $43.33 and a 1 year high of $69.10. The firm has a 50-day moving average of $50.52 and a 200 day moving average of $50.84.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. The firm had revenue of $11.87 billion during the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the business posted $2.05 EPS. On average, research analysts expect that Bristol-Myers Squibb will post 0.59 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th were paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 5.46%. The ex-dividend date was Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. BMO Capital Markets cut their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Barclays cut their price objective on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. StockNews.com downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 15th. Finally, Redburn Atlantic cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $77.00 to $54.00 in a report on Tuesday, February 6th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $60.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.